Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q1 2026 · 10-Q
Revenue$0.00$0.00— vs Q1 2025 Net Income-$8.97M-$8.97MN/M vs Q1 2025 EPS Diluted-$0.22-$0.22N/M vs Q1 2025 Operating Income-$9,803,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end